Outline:
Introduction to allopathic drug management strategies in treating Obesity in Canada.
Introduce current treatment goals, physiologic targets and guiding principles for the clinical drug selection in weight loss and obesity treatment. (10 minutes)
Comparing the 2 major DRUG CLASSES and OFF LABEL drugs used in current established drug management options for obesity and weight loss in Canada:
LABELLED USE FOR OBESITY: 35 minutes
Incretin Mimetics:
1. GLP-1 (glucagon-like peptide-1) therapy
i. liraglutide (Saxenda®)
ii. tirzapatide (Mounjaro®)
iii. semaglutide 2.4mg (Wegovy®)
2. Semaglutide / pancreatic lipid enzyme antagonists
i. orlistat (Xenical®)
Amphetamine based agents:
i. naltrexone/bupropion (Contrave®)
OFF-LABEL USES IN OBESITY: 35 minutes
1. GLP-1 therapy:
i. semaglutide (Ozempic®)
Drug discussion will include (with supportive clinical studies), discussion of mechanisms of action and clinical indications of use, contra-indications of use, side effects of drug use and herb/nutrient interactions. (70 minutes)
Brief look at evolving treatment research and new strategies being investigated including those already FDA approved. (35 minutes)
Conclusion / Summary (5 minutes)
TOTAL: 2 hrs
As presented at our Live 2024 ND Conference: Naturopathic Approaches to Various Disorders. A complete list of webinars from the 2024 Conference can be found here.
Presented by Dr Carol Laic ND MEd